Back to Authors

Nowakowski, Grzegorz S.

https://orcid.org/0000-0002-6955-9393

A5061713890 | I1330342723

Mayo Clinic

Citations 513

Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1742-1744

10.1182/blood-2022-159620

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6618-6620

10.1182/blood-2022-155995

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2362-2364

10.1182/blood-2022-158273

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6489-6491

10.1182/blood-2022-167633

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 561-563

10.1182/blood-2022-158631

Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3811-3813

10.1182/blood-2022-158550

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10391-10393

10.1182/blood-2022-159725

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 569-572

10.1182/blood-2022-162559

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3548-3550

10.1182/blood-2022-170228

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3839-3841

10.1182/blood-2022-157105